Jazz Pharmaceuticals $JAZZ initiated the rolling submission of its New Drug Application (NDA) to the FDA seeking approval for Vyxeos (cytarabine and daunorubicin liposome injection) for the treatment of acute myeloid leukemia (AML), a Breakthrough Therapy-designated indication. The company anticipates completing the filing in early 2017. The drug-maker took the rights to Vyxeos through its acquisition of Celator Pharmaceuticals, earlier in July.